AKROMEGALIYa: VAZhNOST' OTsENKI SISTEMNYKh PROYaVLENIY ZABOLEVANIYa I IKh TERAPII, ROL' ANALOGOV SOMATOSTATINA


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

High mortality rate among patients with acromegaly is associated with prolonged effects of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess. An adequate treatment of acromegaly is to be aimed at these hormones levels reducing, system and metabolic complications treatment and pituitary tumor shrinkage. Mortality rates for this disease have significantly decreased last decades due to the development of effective treatments, particularly modern somatostatin analogues. This group includes the lanreotide Autogel - an effective drug for the treatment of acromegaly which reduces GH and IGF-1 levels and clinical symptoms of the disease.

全文:

受限制的访问

作者简介

M. Antsiferov

V. Pronin

参考

  1. Mestron A, Webb S, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry. Eur J Endocrinol 2004;151:439-46.
  2. Schneider H, Sievers C, Saller B, et al. High prevalence of biochemical acromegaly in primary care patients with elevated IGF-1 levels. Clin Endocrinol (Oxf) 2008;69(3):432-35.
  3. Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004;25(1):102-52.
  4. Sherlock M, Ayuk J, Tomlinson J, et al. Mortality in patients with pituitary disease. Endocr Rev 2010;31(3):301-42.
  5. Holdaway I, Rajasoorya R, Gamble G. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667-74.
  6. Дедов И.И., Мельниченко Г.А. Акромегалия: патогенез, клиника, диагностика, дифференциальная диагностика, методы лечения. Пособие для врачей. М., 2012. 80 с.
  7. Melmed S, Colao A, Barkan A, et al. Acromegaly Consensus Group. Guidelines for acromegaly management: An update. J Clin Endocrinol Metab 2009;94:1509-17.
  8. Heron I, Thomas F, Dero M, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993;76:721-27.
  9. Valery C, Pouget E, Pandit A, et al. 2008. Molecular origin of the selfassembly of lanreotide into nanotubes: a mutational approach. Biophys J 2008;94:1782-95.
  10. Antonijoan R, Barbanoj M, Cordero J, et al. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. J Pharm Pharmacol 2004;56:471-76.
  11. Bronstein M, Musolino N, Jallad R, et al. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf) 2005;63:514-19.
  12. Troconiz I, Cendros J, Peraire C, et al. Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months. Clin Pharmacokinet 2009;48(1):51-62.
  13. Lucas T, Astorga R. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreo-tide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf) 2006;65:320-26.
  14. Lombardi G, Minuto F, Tamburrano G, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest 2009;32(3):202-29.
  15. Schopohl J, Strasburger C, Caird D, et al. Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes 2011;119(3):156-62.
  16. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005;153(6):737-40.
  17. Attanasio R, Lanzi R, Losa M., et al. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 2008;14(7):846-55.
  18. Melmed S, Cook D, Schopohl J, et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 2010;13(1):18-28.
  19. Shimatsu A, Teramoto A, Hizuka N, et al. Efficacy, safety, and pharmacokinetics of sus-tained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism. Endocr J 2013;Jan 19.
  20. Caron P, Beckers A, Cullen D, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002;87(1):99-104.
  21. Gutt B, Bidlingmaier M, Kretschmar K, et al. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes 2005;113(3):139-44.
  22. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004;151:317-24.
  23. Ashwell S, Bevan J, Edwards O, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 2004;150(4):473-80.
  24. Kelly P, Maher K, Chew S, et al. A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide. Endocr Pract 2010;16(2):191-97.
  25. Salvatori R, Nachtigall L, Cook D, et al. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-nave patients with acromegaly. Pituitary 2010;13(2):115-22.
  26. Colao A, Pivonello R, Auriemma R, et al. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 2007;157(5):579-87.
  27. Wuster C, Both S, Cordes U, et al. Primary treatment of acromegaly with high-dose lanreotide: a case series. J Med Case Rep 2010;8(4):85-91.
  28. Kuhn J, Basin C, Mollard M, et al. Effects of the new somatostatin analogue (BIM 23014) on blood glucose homeostasis in normal men. Eur J Clin Invest 1992;22:793-99.
  29. Kasayama S, Otsuki M, Tagaki M, et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000;52:549-55.
  30. Melmed S, Casanueva F, Klibanski A, et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2012;Aug 18.
  31. Иловайская И.А. Кардиологические осложнения акромегалии // Фарматека 2009;10:26-30.
  32. Baldelli R, Ferretti E, Jaffrain-Rea M, et al. Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 1999;84:527-32.
  33. Hradec J, Krai J, Janota T, et al. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol 1999;83:1506-509.
  34. Lombardi G, Colao A, Marzullo P, et al. Multicenter Italian Study Group on Lanreotide. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest 2002;25(11):971-76.
  35. Maison P, Tropeano A, Macquin-Mavier I, et al. Impact of somatostatin analogs on the heart in acromegaly: a meta-analysis. J Clin Endocrinol Metab 2007;92:1743-47.
  36. Fougner S, Borota O, Berg J, et al. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf) 2008;68:458-65.
  37. Florio T, Thellung S, Corsaro A, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf) 2003;59:115-28.
  38. Melmed S, Sternberg R, Cool D, et al. Clinical review: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005;90:4405-10.
  39. Mao Z, Zhu Y, Tang H, et al. Preoperative lanreo-tide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial. Eur J Endocrinol 2010;162(4):661-66.
  40. Giustina A, Chanson P, Bronstein M, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010;95(7):3141-48.
  41. Ronchi C, Boschetti M, Degli Uberti E, et al. Efficacy of a slow-release formulation of lan-reotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol, (Oxf) 2007;67(4):512-19.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2013
##common.cookie##